MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

NCT05090566 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
46
Enrollment
INDUSTRY
Sponsor class

Stopped A business decision was made by Pfizer to terminate the study and not proceed with the Phase 2 expansion of this study. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.

Conditions

Interventions

Sponsor

Pfizer